期刊文献+

MUC1和MUC5AC在弥漫性大B细胞淋巴瘤组织中的表达及意义

Expressions and significances of MUC1 and MUC5AC in diffuse large B cell lymphoma tissues
下载PDF
导出
摘要 目的:分析粘性蛋白1(MUC1)和粘性蛋白5AC(MUC5AC)在弥漫性大B细胞淋巴瘤(DLBCL)组织中的表达水平,探究其临床意义。方法:选择本院2014年1月至2015年6月收治确诊且临床资料完整的DLBCL患者56例为研究对象,另取同期淋巴结反应性增生(RLH)组患者35例为对照组,qRT-PCR及免疫组化检测MUC1和MUC5AC表达水平。结果:DLBCL组患者肿瘤组织中MUC1 mRNA水平显著高于RLH组患者(P<0.05);MUC5AC mRNA水平显著低于RLH组患者(P<0.05);免疫组化结果显示DLBCL组患者MUC1阳性表达率显著高于RLH组,MUC5AC阳性表达率显著低于RLH组(P<0.05);MUC1和MUC5AC表达水平与DLBCL肿瘤分期、B淋巴症状、IPI评分有关(P<0.05);MUC1阴性表达组无进展生存率和总生存率显著高于阳性表达组(P<0.05),MUC5AC阳性表达组无进展生存率和总生存率显著高于阴性表达组(P<0.05);MUC1和MUC5AC表达水平及肿瘤分期是影响DLBCL患者预后的独立危险因素(P<0.05)。结论:MUC1在DLBCL组织中显著表达上调,MUC5AC在DLBCL组织中表达下调,其表达水平与DLBCL临床病理特征相关,影响患者预后。 Objective:To analyze the expression levels of mucin 1(MUC1)and mucin 5AC(MUC5AC)in diffuse large B-cell lymphoma(DLBCL)and explore their clinical significances in DLBCL.Methods:Fifty-six DLBCL patients admitted to our hospital from January 2014 to June 2015 with complete clinical data were selected as the study subjects,another thirty-five patients with lymph node reactive hyperplasia in the same period were selected as control group,qRT-PCR and immunohistochemistry were used to detect the expression levels of MUC1 and MUC5AC.Results:The level of MUC1 mRNA in tumor tissue of group DLBCL was significantly higher than that of group RLH(P<0.05).The level of MUC5AC mRNA was significantly lower than that in group RLH(P<0.05).Immunohistochemical results showed that the positive expression rate of MUC1 in DLBCL group was significantly higher than that in RLH group,and the positive expression rate of MUC5AC in DLBCL group was significantly lower than that in RLH group(P<0.05).The expression levels of MUC1 and MUC5AC were related to DLBCL tumor staging,B lymphatic symptoms and IPI score(P<0.05).The progression-free survival rate and total survival rate of MUC1 negative expression group were significantly higher than those of positive expression group(P<0.05),and the progression-free survival rate and total survival rate of MUC5AC positive expression group were significantly higher than those of negative expression group(P<0.05).The expressions of MUC1 and MUC5AC and tumor stage were independent risk factors for the prognosis of DLBCL patients(P<0.05).Conclusion:The expression of MUC1 is up-regulated in DLBCL,and the expression of MUC5AC is down-regulated in DLBCL,their expression levels correlative with the clinicopathological features of DLBCL and affect the prognosis of patients.
作者 刘伟 叶绥艳 Liu Wei;Ye Suiyan(Department of Hematology,the First Hospital of Yulin,Shaanxi Yulin 719000,China.)
出处 《现代肿瘤医学》 CAS 2020年第16期2876-2880,共5页 Journal of Modern Oncology
关键词 粘性蛋白1 粘性蛋白5AC 弥漫性大B细胞淋巴瘤 临床意义 mucins 1 mucins 5AC diffuse large B cell lymphoma clinical significance
  • 相关文献

参考文献5

二级参考文献27

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献261

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部